Guardant Health Expands Colon Cancer Screening Access with Nationwide Mobile Tour
Event summary
- Guardant Health launched Shield Across America, a coast-to-coast mobile screening tour bringing its Shield colon cancer blood test to over 100 communities.
- The tour targets rural areas with high CRC incidence and mortality rates, coinciding with National CRC Awareness Month.
- Shield is the first and only FDA-approved blood test for primary colorectal cancer screening, covered by Medicare and other major insurers.
- The test has shown 93% completion rate in real-world use, significantly improving screening adherence.
The big picture
Guardant Health's mobile screening tour represents a strategic push to address the significant gap in colorectal cancer screening, particularly in underserved rural areas. With CRC being the second leading cause of cancer deaths in the U.S., the company's initiative aligns with broader industry efforts to make preventive care more accessible. The tour's success could set a precedent for how other diagnostic companies approach market expansion in hard-to-reach populations.
What we're watching
- Adoption Pace
- How quickly Shield can gain traction in rural communities with historically low screening rates.
- Regulatory Impact
- Whether the National Comprehensive Cancer Network's inclusion of Shield will accelerate guideline adoptions by other major clinical bodies.
- Competitive Response
- How traditional screening methods and other diagnostic companies will react to Guardant's mobile screening strategy.
Related topics